{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:44Z","timestamp":1792057604549,"version":"4.4.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 AI150334"],"award-info":[{"award-number":["R01 AI150334"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.virol.2024.110362","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:55:50Z","timestamp":1734436550000},"page":"110362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["30 years of HIV therapy: Current and future antiviral drug targets"],"prefix":"10.1016","volume":"603","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-2382","authenticated-orcid":false,"given":"Julius","family":"Nuwagaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 10","key":"10.1016\/j.virol.2024.110362_bib1","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1099\/vir.0.80137-0","article-title":"Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release","volume":"85","author":"Abdurahman","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2024.110362_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coviro.2015.06.007","article-title":"CCR5\u039432 mutation and HIV infection: basis for curative HIV therapy","volume":"14","author":"Allers","year":"2015","journal-title":"Curr. Opin. Virol."},{"issue":"17","key":"10.1016\/j.virol.2024.110362_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00636-22","article-title":"Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compound","volume":"96","author":"Anang","year":"2022","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2024.110362_bib4","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/00002030-198800001-00009","article-title":"Epidemiology of HIV infection and AIDS: incubation and infectious periods, survival and vertical transmission","volume":"2","author":"Anderson","year":"1988","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.virol.2024.110362_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0092-8674(89)90289-4","article-title":"Tat trans-activates the human immunodeficiency virus through a nascent RNA target","volume":"59","author":"Berkhout","year":"1989","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: a review in multidrug-resistant HIV-1 infection","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.virol.2024.110362_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00462-23","article-title":"Biological and structural analyses of new potent allosteric inhibitors of HIV-1 integrase","volume":"67","author":"Bonnard","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/srep36485","article-title":"Dynamic oligomerization of integrase orchestrates HIV nuclear entry","volume":"6","author":"Borrenberghs","year":"2016","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.virol.2024.110362_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1517\/13543784.11.12.1837","article-title":"Enfuvirtide","volume":"11","author":"Chen","year":"2002","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11060611","article-title":"HIV latency in myeloid cells: challenges for a cure","volume":"11","author":"Chitrakar","year":"2022","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/jmbi.1993.1128","article-title":"High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region","volume":"230","author":"Churcher","year":"1993","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-3542(98)00025-4","article-title":"The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5\u201310 April 1998.1","volume":"38","author":"De Clercq","year":"1998","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.virol.2024.110362_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fvl.12.56","article-title":"The molecular biology of HIV integrase","volume":"7","author":"Craigie","year":"2012","journal-title":"Future Virol."},{"issue":"22","key":"10.1016\/j.virol.2024.110362_bib18","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.212285299","article-title":"A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export","volume":"99","author":"Daelemans","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"issue":"9903","key":"10.1016\/j.virol.2024.110362_bib20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib21","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"12","key":"10.1016\/j.virol.2024.110362_bib22","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: international AIDS society global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2024.110362_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fimmu.2015.00277","article-title":"Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection","volume":"6","author":"Van Der Ryst","year":"2015","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib24","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1073\/pnas.090576697","article-title":"A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5","volume":"97","author":"Dragic","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"15","key":"10.1016\/j.virol.2024.110362_bib25","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1074\/jbc.RA119.007360","article-title":"HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry","volume":"294","author":"Eggink","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2747","article-title":"The structural biology of HIV-1: mechanistic and therapeutic insights","volume":"10","author":"Engelman","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1073\/pnas.86.5.1495","article-title":"Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA","volume":"86","author":"Felber","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.virol.2024.110362_bib29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2013.03.026","article-title":"The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets","volume":"442","author":"Flynn","year":"2013","journal-title":"Virology"},{"issue":"17","key":"10.1016\/j.virol.2024.110362_bib31","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/QAD.0000000000002011","article-title":"Antibody-dependent cellular cytotoxicity in HIV infection","volume":"32","author":"Forthal","year":"2018","journal-title":"Aids"},{"issue":"8","key":"10.1016\/j.virol.2024.110362_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 assembly, release and maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"issue":"13","key":"10.1016\/j.virol.2024.110362_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2222073120","article-title":"Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity","volume":"120","author":"Fritschi","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"18","key":"10.1016\/j.virol.2024.110362_bib34","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1073\/pnas.94.18.9825","article-title":"HIV-1 infection of nondividing cells through the recognition of integrase by the importin\/karyopherin pathway","volume":"94","author":"Gallay","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4648","key":"10.1016\/j.virol.2024.110362_bib35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.6200936","article-title":"Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS","volume":"224","author":"Gallo","year":"1984","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.35772\/ghm.2023.01013","article-title":"Four decades of continuing innovations in the development of antiretroviral therapy for HIV\/AIDS: progress to date and future challenges","volume":"5","author":"Ghosh","year":"2023","journal-title":"Glob Health Med."},{"issue":"11","key":"10.1016\/j.virol.2024.110362_bib37","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110362_bib38","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44360","article-title":"Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members","volume":"8","author":"Gonzalo-Gil","year":"2019","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkh330","article-title":"Resistance to enfuvirtide, the first HIV fusion inhibitor","volume":"54","author":"Greenberg","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/v7010199","article-title":"HIV-1 replication and the cellular eukaryotic translation apparatus","volume":"7","author":"Guerrero","year":"2015","journal-title":"Viruses"},{"issue":"7751","key":"10.1016\/j.virol.2024.110362_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib42","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"The Lancet HIV"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib43","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"The Lancet HIV"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2024.110362_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2022.08.011","article-title":"Cell-based and cell-free firefly luciferase complementation assay to quantify Human Immunodeficiency Virus type 1 Rev-Rev interaction","volume":"576","author":"Hansen","year":"2022","journal-title":"Virology"},{"issue":"42","key":"10.1016\/j.virol.2024.110362_bib46","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"He","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/bfgp\/elz021","article-title":"CRISPR therapy towards an HIV cure","volume":"19","author":"Herrera-Carrillo","year":"2020","journal-title":"Brief Funct. Genom."},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib48","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/jvi.69.3.1612-1620.1995","article-title":"Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor","volume":"69","author":"Herrmann","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110362_bib49","first-page":"dkae305","article-title":"Lenacapavir to prevent HIV infection: current prices versus estimated costs of production","author":"Hill","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib50","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib51","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006882","article-title":"HIV-1 reverse transcription","volume":"2","author":"Hu","year":"2012","journal-title":"Cold Spring Harb. Perspect Med."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.572905","article-title":"Ritonavir-boosted protease inhibitors in HIV therapy","volume":"43","author":"Hull","year":"2011","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021563","article-title":"A CRISPR-cas cure for HIV\/AIDS","volume":"24","author":"Hussein","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virol.2024.110362_bib54","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","article-title":"Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy","volume":"8","author":"Iacob","year":"2017","journal-title":"Front. Microbiol."},{"issue":"43","key":"10.1016\/j.virol.2024.110362_bib55","volume":"97","author":"Jacobson","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-5-63","article-title":"Dominant negative mutant Cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat","volume":"5","author":"Jadlowsky","year":"2008","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00705-019-04153-9","article-title":"Examining pharmacodynamic and pharmacokinetic properties of eleven analogues of saquinavir for HIV protease inhibition","volume":"164","author":"Jayaswal","year":"2019","journal-title":"Arch. Virol."},{"issue":"14","key":"10.1016\/j.virol.2024.110362_bib58","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1080\/07391102.2021.1885496","article-title":"Evaluation of binding of potential ADMET\/tox screened saquinavir analogues for inhibition of HIV-protease via molecular dynamics and binding free energy calculations","volume":"40","author":"Jayaswal","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2024.110362_bib59","series-title":"New Hope for Cure of HIV-Infected Patients","first-page":"10.1097","author":"Jiao","year":"2024"},{"key":"10.1016\/j.virol.2024.110362_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2787731","article-title":"Factors influencing survival status of HIV\/AIDS after HAART in huzhou city, eastern China","volume":"2022","author":"Jin","year":"2022","journal-title":"Can. J. Infect Dis. Med. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.virusres.2008.01.003","article-title":"Novel HIV-1 reverse transcriptase inhibitors","volume":"134","author":"Jochmans","year":"2008","journal-title":"Virus Res."},{"issue":"9","key":"10.1016\/j.virol.2024.110362_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2020.06.003","article-title":"Structural biology of HIV integrase strand transfer inhibitors","volume":"41","author":"J\u00f3\u017awik","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib63","doi-asserted-by":"crossref","first-page":"a006916","DOI":"10.1101\/cshperspect.a006916","article-title":"Transcriptional and posttranscriptional regulation of HIV-1 gene expression","volume":"2","author":"Karn","year":"2012","journal-title":"Cold Spring Harb. Perspect Med."},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/v14061179","article-title":"Beyond inhibition: a novel strategy of targeting HIV-1 protease to eliminate viral reservoirs","volume":"14","author":"Kim","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.virol.2024.110362_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2023.101151","article-title":"Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression","volume":"5","author":"Kleinmann","year":"2023","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"issue":"13","key":"10.1016\/j.virol.2024.110362_bib66","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","author":"Kohl","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110362_bib67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2121-6-20","article-title":"Identification of a novel Rev-interacting cellular protein","volume":"6","author":"Kramer-H\u00e4mmerle","year":"2005","journal-title":"BMC Cell Biol."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib70","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","article-title":"Pharmacokinetic enhancers in HIV therapeutics","volume":"53","author":"Larson","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib71","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"14","key":"10.1016\/j.virol.2024.110362_bib72","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.vaccine.2012.01.055","article-title":"A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies","volume":"30","author":"Liao","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib73","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib74","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1631\/jzus.B1400059","article-title":"Mechanism and factors that control HIV-1 transcription and latency activation","volume":"15","author":"Liu","year":"2014","journal-title":"J. Zhejiang Univ. - Sci. B"},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/acsinfecdis.8b00336","article-title":"Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease","volume":"5","author":"Lockbaum","year":"2019","journal-title":"ACS Infect. Dis."},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/v2020574","article-title":"CCR5: from natural resistance to a new anti-HIV strategy","volume":"2","author":"Lopalco","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110362_bib77","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"issue":"6212","key":"10.1016\/j.virol.2024.110362_bib78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/338254a0","article-title":"The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA","volume":"338","author":"Malim","year":"1989","journal-title":"Nature"},{"issue":"8024","key":"10.1016\/j.virol.2024.110362_bib79","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/d41586-024-02463-w","article-title":"Seventh patient'cured'of HIV: why scientists are excited","volume":"632","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib80","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.sbi.2013.03.007","article-title":"HIV-1 envelope glycoprotein structure","volume":"23","author":"Merk","year":"2013","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"20","key":"10.1016\/j.virol.2024.110362_bib81","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110362_bib82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/DDDT.S273660","article-title":"Efficacy and safety profile of fostemsavir for the treatment of people with human immunodeficiency virus-1 (HIV-1): current evidence and place in therapy","volume":"16","author":"Muccini","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: recent estimates and future implications","volume":"26","author":"Nakagawa","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110362_bib84","article-title":"NIH","year":"2024","journal-title":"FDA-Approved HIV Medicines"},{"issue":"23","key":"10.1016\/j.virol.2024.110362_bib85","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305103120","article-title":"HIV-1 usurps transcription start site heterogeneity of host RNA polymerase II to maximize replication fitness","volume":"120","author":"Nikolaitchik","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.virol.2024.110362_bib86","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/QAD.0b013e32835f1d68","article-title":"Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria","volume":"27","author":"Nosyk","year":"2013","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.virol.2024.110362_bib87","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1086\/646609","article-title":"Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US department of defense HIV natural history study","volume":"200","author":"Okulicz","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"25","key":"10.1016\/j.virol.2024.110362_bib88","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa2210005","article-title":"Second-line switch to dolutegravir for treatment of HIV infection","volume":"388","author":"Ombajo","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.virol.2024.110362_bib89","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tins.2020.06.007","article-title":"The paradox of HIV blood-brain barrier penetrance and antiretroviral drug delivery deficiencies","volume":"43","author":"Osborne","year":"2020","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib90","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s43440-021-00257-9","article-title":"An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein\u2014short review","volume":"73","author":"Pai","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"8","key":"10.1016\/j.virol.2024.110362_bib91","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tips.2023.05.002","article-title":"Lenacapavir (Sunlenca\u00ae) for the treatment of HIV-1","volume":"44","author":"Patel","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib92","first-page":"495","article-title":"Pharmacological outlook of lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor","volume":"31","author":"Di Perri","year":"2023","journal-title":"Infez Med"},{"key":"10.1016\/j.virol.2024.110362_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2022.834013","article-title":"Treatment of tuberculosis and the drug interactions associated with HIV-TB co-infection treatment","volume":"3","author":"Pooranagangadevi","year":"2022","journal-title":"Front. Trop. Dis."},{"key":"10.1016\/j.virol.2024.110362_bib94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2018.07.040","article-title":"A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference","volume":"156","author":"Prado","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib95","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas","year":"2020","journal-title":"The Lancet Microbe"},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib96","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.3390\/v7062760","article-title":"HIV rev assembly on the rev response element (RRE): a structural perspective","volume":"7","author":"Rausch","year":"2015","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib97","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/jac\/dkv026","article-title":"Virological failure of patients on maraviroc-based antiretroviral therapy","volume":"70","author":"Raymond","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib98","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","article-title":"The prevalence of antiretroviral drug resistance in the United States","volume":"18","author":"Richman","year":"2004","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1742-4690-10-43","article-title":"A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations","volume":"10","author":"Roche","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2024.110362_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103896","article-title":"Ageing with HIV: challenges and biomarkers","volume":"77","author":"Rod\u00e9s","year":"2022","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19042359","article-title":"Aging with HIV: increased risk of HIV comorbidities in older adults","volume":"19","author":"Roomaney","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.virol.2024.110362_bib102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4690-2-11","article-title":"The Vpr protein from HIV-1: distinct roles along the viral life cycle","volume":"2","author":"Le Rouzic","year":"2005","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2024.110362_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","author":"S\u00e1ez-Ciri\u00f3n","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib104","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jinf.2019.03.003","article-title":"Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics","volume":"78","author":"Sarfo","year":"2019","journal-title":"J. Infect."},{"key":"10.1016\/j.virol.2024.110362_bib106","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.2741\/1403","article-title":"Role of viral regulatory and accessory proteins in HIV-1 replication","volume":"9","author":"Seelamgari","year":"2004","journal-title":"Front. Biosci."},{"issue":"19","key":"10.1016\/j.virol.2024.110362_bib107","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.virol.2024.110362_bib108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0753-3322(99)80063-8","article-title":"Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1","volume":"53","author":"Shafer","year":"1999","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect Chemother."},{"issue":"9","key":"10.1016\/j.virol.2024.110362_bib110","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.00274-08","article-title":"Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication","volume":"52","author":"Shuck-Lee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsle.2004.09.040","article-title":"HIV and the CCR5-\u039432 resistance allele","volume":"241","author":"de Silva","year":"2004","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Lett."},{"issue":"12","key":"10.1016\/j.virol.2024.110362_bib112","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","article-title":"Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors","volume":"40","author":"Smith","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.virol.2024.110362_bib113","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110362_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1133407","article-title":"Strategies to overcome HIV drug resistance-current and future perspectives","volume":"14","author":"Temereanca","year":"2023","journal-title":"Front. Microbiol."},{"issue":"11","key":"10.1016\/j.virol.2024.110362_bib115","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/S2352-3018(17)30183-2","article-title":"U=U taking off in 2017","volume":"4","author":"The Lancet","year":"2017","journal-title":"The Lancet HIV"},{"issue":"3","key":"10.1016\/j.virol.2024.110362_bib116","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/1570162X14999160224103555","article-title":"HIV-1 capsid inhibitors as antiretroviral agents","volume":"14","author":"Thenin-Houssier","year":"2016","journal-title":"Curr. HIV Res."},{"issue":"20","key":"10.1016\/j.virol.2024.110362_bib117","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1128\/JVI.01109-10","article-title":"A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5","volume":"84","author":"Tilton","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib118","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11904-019-00480-3","article-title":"Recent advances in the development of integrase inhibitors for HIV treatment","volume":"17","author":"Trivedi","year":"2020","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.virol.2024.110362_bib119","series-title":"AIDS Statistics \u2014 Fact Sheet","first-page":"6","author":"Unaids","year":"2023"},{"issue":"12","key":"10.1016\/j.virol.2024.110362_bib120","doi-asserted-by":"crossref","first-page":"eadl0368","DOI":"10.1126\/sciadv.adl0368","article-title":"JAK\/STAT signaling pathway affects CCR5 expression in human CD4(+) T cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib122","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0092-8674(00)80939-3","article-title":"A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA","volume":"92","author":"Wei","year":"1998","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.virol.2024.110362_bib123","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: cell binding and entry","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harb. Perspect Med."},{"issue":"11","key":"10.1016\/j.virol.2024.110362_bib124","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1286-4579(03)00187-4","article-title":"Gene transcription in HIV infection","volume":"5","author":"Wu","year":"2003","journal-title":"Microb. Infect."},{"key":"10.1016\/j.virol.2024.110362_bib125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Xavier Ruiz","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"5","key":"10.1016\/j.virol.2024.110362_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.virol.2024.110362_bib127","first-page":"775","article-title":"Pharmacokinetic enhancers for HIV drugs","volume":"10","author":"Xu","year":"2009","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.virol.2024.110362_bib128","article-title":"Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts","volume":"2","author":"Yaffe","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2045-3701-2-32","article-title":"Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy","volume":"2","author":"Yang","year":"2012","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib130","article-title":"Improved pharmacological and structural properties of HIV fusion inhibitor AP3 over enfuvirtide: highlighting advantages of artificial peptide strategy","volume":"5","author":"Zhu","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.virol.2024.110362_bib131","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1038\/s41467-024-51414-6","article-title":"Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.virol.2024.110362_bib132","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01251-23","article-title":"Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-na\u00efve and treatment-experienced individuals in Botswana","volume":"11","author":"Zuze","year":"2023","journal-title":"Microbiol. Spectr."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:58:14Z","timestamp":1769950694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224003866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":132,"alternative-id":["S0042682224003866"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110362","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"30 years of HIV therapy: Current and future antiviral drug targets","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110362"}}